KREBS BIOCHEMICALS & INDUSTRIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.01 INR | +2.61% |
|
+3.34% | -6.80% |
| Sales 2022 | 587M 7.04M | Sales 2023 | 521M 6.25M | Capitalization | 1.22B 14.58M |
|---|---|---|---|---|---|
| Net income 2022 | -445M -5.34M | Net income 2023 | -247M -2.96M | EV / Sales 2022 | 7.71 x |
| Net Debt 2022 | 1.43B 17.15M | Net Debt 2023 | 1.83B 21.98M | EV / Sales 2023 | 5.85 x |
| P/E ratio 2022 |
-6.94
x | P/E ratio 2023 |
-4.92
x | Employees | 210 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.45% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.61% | ||
| 1 week | +3.34% | ||
| Current month | +19.65% | ||
| 1 month | +9.84% | ||
| 3 months | +1.45% | ||
| 6 months | +6.86% | ||
| Current year | -6.80% |
1 week
68.40
74.50
1 month
60.0074.50
Current year
60.0084.49
1 year
59.3093.20
3 years
51.10227.95
5 years
51.10227.95
10 years
18.50227.95
| Managers | Title | Age | Since |
|---|---|---|---|
Jitendra Shah
CEO | Chief Executive Officer | - | 09/21/09 |
| Founder | 74 | 02/91/02 | |
Ritesh Jain
DFI | Director of Finance/CFO | - | 03/23/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 26/00/26 | |
| Founder | 74 | 02/91/02 | |
Avinash Ravi
BRD | Director/Board Member | 45 | 01/02/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 73.01 | +2.61% | 265 |
| 25/24/25 | 71.15 | -0.85% | 46 |
| 24/24/24 | 71.76 | -1.16% | 1,637 |
| 23/24/23 | 72.6 | +1.30% | 723 |
| 22/24/22 | 71.67 | +1.44% | 84 |
Delayed Quote Bombay S.E., April 26, 2024 at 03:30 pm IST
More quotes
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Companyâs pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
Sector
Pharmaceuticals
Calendar
20/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.80% | 18.88M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- KREBSBIO Stock
